 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || 5-ALA with CV01 / Alpheus Medical
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma (clinicaltrials.gov) - Feb 22, 2024
P1, N=22, Active, not recruiting, Sponsor: Alpheus Medical, Inc.
Recruiting --> Active, not recruiting | N=48 --> 22 | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- || 5-ALA with CV01 / Alpheus Medical
Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma (clinicaltrials.gov) - Jun 8, 2023
P1, N=48, Recruiting, Sponsor: Alpheus Medical, Inc.
Recruiting --> Active, not recruiting | N=48 --> 22 | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 N=33 --> 48 | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2023
- | 5-ALA with CV01 / Alpheus Medical
Trial completion date: Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma (clinicaltrials.gov) - Jul 27, 2022
P1, N=33, Recruiting, Sponsor: Alpheus Medical, Inc.
N=33 --> 48 | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2023 Trial completion date: Sep 2023 --> Apr 2024
- || 5-ALA with CV01 / Alpheus Medical
Enrollment open: Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma (clinicaltrials.gov) - Jul 8, 2022
P1, N=33, Recruiting, Sponsor: Alpheus Medical, Inc.
Trial completion date: Sep 2023 --> Apr 2024 Not yet recruiting --> Recruiting
- | 5-ALA with CV01 / Alpheus Medical
New P1 trial: Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma (clinicaltrials.gov) - May 5, 2022
P1, N=33, Not yet recruiting, Sponsor: Alpheus Medical, Inc.